Radiopharmaceuticals

Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies

Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies

Aptevo Therapeutics and Niowave Inc. have formed a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's targeting platforms with Niowave's isotope supply capabilities to address a $17 billion market.

June 9, 2026
LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support

LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support

LabConnect's collaboration with The Bracken Group addresses the growing demand for specialized radiopharmaceutical expertise in clinical trials, positioning the partnership to better serve biotech and pharmaceutical companies developing targeted treatments and diagnostics.

September 23, 2025
ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies

ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies

ARTBIO enhances its board with four industry veterans to propel its innovative alpha radioligand therapies, marking a pivotal step in its mission to revolutionize cancer treatment.

August 7, 2025